ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

9:00AM-10:30AM: Abstract Number: 1030

Diagnostic Usefulness of Anti-PPM1A-IgM in Patients with Ankylosing Spondylitis

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 0619

Differences Between Patients in Remission with Active Rheumatoid Arthritis by Histological and Molecular Comparisons

RA – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0999

Differences in Chromatin Accessibility Pre- and Post-Induction Therapy in Pediatric Lupus

SLE – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 0844

Differences in Skin Advanced Glycation End-Products Levels Between Subgroups of Achilles Tendinopathy

Orthopedics, Low Back Pain, and Rehabilitation Poster

9:00AM-10:30AM: Abstract Number: 0668

Differential Expression of Interferon Related Genes in SLE Patients of Asian and European Ancestries Abstract

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 1039

Differential Retention of Adalimumab and Etanercept Biosimilars Compared to Originator Treatments: Results of a Retrospective French Multicentre Study

Spondyloarthritis Including PsA – Treatment Poster II: Mixed

9:00AM-10:30AM: Abstract Number: 0833

Disability Among Persons with Chronic Severe Back Pain: Results from a Nationally Representative Population Based Sample

Orthopedics, Low Back Pain, and Rehabilitation Poster

9:00AM-10:30AM: Abstract Number: 1070

Discordance of Patient, Physician and Nurse Practitioner Assessment of Disease Burden in Systemic Sclerosis

Systemic Sclerosis and Related Disorders – Clinical Poster I

9:00AM-10:30AM: Abstract Number: 1013

Discriminatory Capacity of the ASAS Health Index in Patients with Axial Spondyloarthritis Treated in a Tight Control Setting versus Standard of Care

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 0712

Disease Prevalence and Patient Characteristics in Patients with and Without Scleroderma Renal Crisis – A National US-based Inpatient Comparison Study

Epidemiology and Public Health Poster I

9:00AM-10:30AM: Abstract Number: 1054

Distinct Differences in Complement Perturbation Between Scleroderma-related Interstitial Lung Disease with and Without Emphysema

Systemic Sclerosis and Related Disorders – Clinical Poster I

9:00AM-10:30AM: Abstract Number: 0625

Distinct Effects of JAK Inhibitor and TNF Inhibitors on Circulating B Cell Phenotypes in Rheumatoid Arthritis Patients

RA – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0687

DNA- and NET-Binding Beta-2 Glycoprotein I in a Large Cohort of Antiphospholipid Antibody-Positive Patients

Antiphospholipid Syndrome Poster

9:00AM-10:30AM: Abstract Number: 1003

Does LLDAS Definition Match the Rheumatologist Opinion? The First Visit Evaluation of a Longinudital Spanish Multicenter Study to Assess Reasons of Disagreement

SLE – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 0779

Early Experience of Breakthrough COVID-19 Infections in Patients Who Received Pre-exposure Prophylaxis with Tixagevimab/cilgavimab

Infection-related Rheumatic Disease Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].